Carmen Tur1, Sreeram Ramagopalan1, Daniel R Altmann1, Benedetta Bodini1, Mara Cercignani1, Zhaleh Khaleeli1, David H Miller1, Alan J Thompson1, Olga Ciccarelli2. 1. From the Departments of Brain Repair and Rehabilitation (C.T., B.B., Z.K., A.J.T., O.C.) and Neuroinflammation (D.R.A., D.H.M.), University College of London Institute of Neurology, UK; Multiple Sclerosis Centre of Catalonia (Cemcat) (C.T.), Neurology-Neuroimmunology Department, Vall d'Hebron University Hospital, Barcelona, Spain; Blizard Institute (S.R.), Queen Mary University of London; Medical Statistics Department (D.R.A.), London School of Hygiene and Tropical Medicine, University of London; Clinical Imaging Sciences Centre (M.C.), Brighton and Sussex Medical School, Falmer, East Sussex; and National Institute for Health Research (NIHR) University College London Hospitals (UCLH) Biomedical Research Centre, UK. 2. From the Departments of Brain Repair and Rehabilitation (C.T., B.B., Z.K., A.J.T., O.C.) and Neuroinflammation (D.R.A., D.H.M.), University College of London Institute of Neurology, UK; Multiple Sclerosis Centre of Catalonia (Cemcat) (C.T.), Neurology-Neuroimmunology Department, Vall d'Hebron University Hospital, Barcelona, Spain; Blizard Institute (S.R.), Queen Mary University of London; Medical Statistics Department (D.R.A.), London School of Hygiene and Tropical Medicine, University of London; Clinical Imaging Sciences Centre (M.C.), Brighton and Sussex Medical School, Falmer, East Sussex; and National Institute for Health Research (NIHR) University College London Hospitals (UCLH) Biomedical Research Centre, UK. o.ciccarelli@ucl.ac.uk.
Abstract
OBJECTIVES: To investigate whether (1) there were differences between HLA-DRB1*15-positive and -negative patients at baseline, and (2) HLA-DRB1*15-positive patients showed a greater development of brain and spinal cord damage, as assessed by MRI, and greater progression of disability, during a 5-year follow-up, compared with HLA-DRB1*15-negative patients. METHODS: HLA-DRB1*15 typing was performed in 41 patients with primary progressive multiple sclerosis (PPMS) who were recruited within 5 years of symptom onset. All patients and 18 healthy controls were studied clinically and with MRI at baseline, and every 6 months for 3 years, and then at 5 years. Magnetization transfer ratio parameters and volumes for brain gray matter and normal-appearing white matter, brain T2 lesion load, and spinal cord cross-sectional area were obtained. Patient disability was assessed at each visit using the Expanded Disability Status Scale and Multiple Sclerosis Functional Composite subscores. RESULTS: There were no significant differences between HLA-DRB1*15-positive and -negative patients at baseline. HLA-DRB1*15-positive patients showed a greater decline in brain magnetization transfer ratio for gray matter and normal-appearing white matter (both p = 0.005) than HLA-DRB1*15-negative patients over 5 years, while the same parameters did not change over time in healthy controls. HLA-DRB1*15-positive patients also showed a trend toward a faster increase in brain T2 lesion load than HLA-DRB1*15-negative patients (0.29 [95% confidence interval 0.20-0.38] vs 0.21 [0.13-0.30] mL/mo, p = 0.085) and higher T2 lesion volumes at all time points (average difference [95% confidence interval]: 10.58 mL [7.09-14.07], p < 0.001) during the follow-up, after adjusting for disease duration. CONCLUSIONS: These findings suggest that HLA-DRB1*15 influences the progression of brain pathology in PPMS.
OBJECTIVES: To investigate whether (1) there were differences between HLA-DRB1*15-positive and -negative patients at baseline, and (2) HLA-DRB1*15-positive patients showed a greater development of brain and spinal cord damage, as assessed by MRI, and greater progression of disability, during a 5-year follow-up, compared with HLA-DRB1*15-negative patients. METHODS:HLA-DRB1*15 typing was performed in 41 patients with primary progressive multiple sclerosis (PPMS) who were recruited within 5 years of symptom onset. All patients and 18 healthy controls were studied clinically and with MRI at baseline, and every 6 months for 3 years, and then at 5 years. Magnetization transfer ratio parameters and volumes for brain gray matter and normal-appearing white matter, brain T2 lesion load, and spinal cord cross-sectional area were obtained. Patient disability was assessed at each visit using the Expanded Disability Status Scale and Multiple Sclerosis Functional Composite subscores. RESULTS: There were no significant differences between HLA-DRB1*15-positive and -negative patients at baseline. HLA-DRB1*15-positive patients showed a greater decline in brain magnetization transfer ratio for gray matter and normal-appearing white matter (both p = 0.005) than HLA-DRB1*15-negative patients over 5 years, while the same parameters did not change over time in healthy controls. HLA-DRB1*15-positive patients also showed a trend toward a faster increase in brain T2 lesion load than HLA-DRB1*15-negative patients (0.29 [95% confidence interval 0.20-0.38] vs 0.21 [0.13-0.30] mL/mo, p = 0.085) and higher T2 lesion volumes at all time points (average difference [95% confidence interval]: 10.58 mL [7.09-14.07], p < 0.001) during the follow-up, after adjusting for disease duration. CONCLUSIONS: These findings suggest that HLA-DRB1*15 influences the progression of brain pathology in PPMS.
Authors: G R Cutter; M L Baier; R A Rudick; D L Cookfair; J S Fischer; J Petkau; K Syndulko; B G Weinshenker; J P Antel; C Confavreux; G W Ellison; F Lublin; A E Miller; S M Rao; S Reingold; A Thompson; E Willoughby Journal: Brain Date: 1999-05 Impact factor: 13.501
Authors: N A Losseff; S L Webb; J I O'Riordan; R Page; L Wang; G J Barker; P S Tofts; W I McDonald; D H Miller; A J Thompson Journal: Brain Date: 1996-06 Impact factor: 13.501
Authors: A J Thompson; X Montalban; F Barkhof; B Brochet; M Filippi; D H Miller; C H Polman; V L Stevenson; W I McDonald Journal: Ann Neurol Date: 2000-06 Impact factor: 10.422
Authors: Klaus Schmierer; Francesco Scaravilli; Daniel R Altmann; Gareth J Barker; David H Miller Journal: Ann Neurol Date: 2004-09 Impact factor: 10.422
Authors: Noriko Isobe; Anisha Keshavan; Pierre-Antoine Gourraud; Alyssa H Zhu; Esha Datta; Regina Schlaeger; Stacy J Caillier; Adam Santaniello; Antoine Lizée; Daniel S Himmelstein; Sergio E Baranzini; Jill Hollenbach; Bruce A C Cree; Stephen L Hauser; Jorge R Oksenberg; Roland G Henry Journal: JAMA Neurol Date: 2016-07-01 Impact factor: 18.302
Authors: T Matsushita; L Madireddy; T Sprenger; P Khankhanian; S Magon; Y Naegelin; E Caverzasi; R L P Lindberg; L Kappos; S L Hauser; J R Oksenberg; R Henry; D Pelletier; S E Baranzini Journal: Genes Brain Behav Date: 2015-03-05 Impact factor: 3.449
Authors: Alan J Thompson; William Carroll; Olga Ciccarelli; Giancarlo Comi; Anne Cross; Alexis Donnelly; Anthony Feinstein; Robert J Fox; Anne Helme; Reinhard Hohlfeld; Robert Hyde; Pamela Kanellis; Douglas Landsman; Catherine Lubetzki; Ruth Ann Marrie; Julia Morahan; Xavier Montalban; Bruno Musch; Sarah Rawlings; Marco Salvetti; Finn Sellebjerg; Caroline Sincock; Kathryn E Smith; Jon Strum; Paola Zaratin; Timothy Coetzee Journal: Mult Scler Date: 2021-12-01 Impact factor: 6.312
Authors: C Tur; A Eshaghi; D R Altmann; T M Jenkins; F Prados; F Grussu; T Charalambous; A Schmidt; S Ourselin; J D Clayden; C A M G Wheeler-Kingshott; A J Thompson; O Ciccarelli; A T Toosy Journal: Sci Rep Date: 2018-07-16 Impact factor: 4.379
Authors: Klarissa Hanja Stürner; Inessa Siembab; Gerhard Schön; Jan-Patrick Stellmann; Nika Heidari; Boris Fehse; Christoph Heesen; Thomas H Eiermann; Roland Martin; Thomas Mc Binder Journal: Mult Scler J Exp Transl Clin Date: 2019-12-09